Advanced Therapies Include Responsive Neurostimulation and Vagus Nerve Stimulation
The epilepsy team at Cincinnati Children’s is expanding its investment in neuromodulation devices as the next treatment frontier for patients with drug-refractory seizures who aren’t surgical candidates.
In 2024, pediatric neurologist and epilepsy specialist Hans Greiner, MD, co-director of the Epilepsy Surgery Program, launched a dedicated clinic for patients with neuromodulation devices.
“We’ve opened our intracranial stimulation umbrella to anyone with drug-resistant epilepsy,” Greiner says. “We now have a clinic with the sole focus of managing these patients’ devices, and we want providers to know that we offer options for many patients who didn’t have any options in the past.”
An “Iterative Process” to Controlling Seizures
In 2019, Cincinnati Children’s was one of the first pediatric hospitals in the country to use responsive neurostimulation (RNS) off-label to treat children with well-localized seizure foci. Initially, the epilepsy team used RNS to treat only patients with focal drug-refractory seizures who weren’t surgical candidates. That first year, they implanted one or two RNS devices in patients, Greiner says, and integrated those patients into existing clinics.
Since then, neurosurgeons Francesco Mangano, DO, and Jesse Skoch, MD, have developed significant experience placing RNS electrodes in multiple brain regions, including gray matter and thalamus (deep) targets.
Thalamic targets are viewed as more beneficial for stopping generalized seizures.